We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+12.64%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$3.53B
AUM Growth
+$116M
Cap. Flow
-$73.8M
Cap. Flow %
-2.09%
Top 10 Hldgs %
47.92%
Holding
99
New
17
Increased
28
Reduced
21
Closed
18

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$51.2M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$50.1M
3
FOLD
Amicus Therapeutics
FOLD
+$40.3M
4
CNC icon
Centene
CNC
+$37.3M
5
STOK icon
Stoke Therapeutics
STOK
+$27.4M

Top Sells

Rank Stock Value
1
IFRX icon
InflaRx
IFRX
+$82.5M
2
ARRY
Array Biopharma Inc
ARRY
+$62.3M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$49.3M
4
PEN icon
Penumbra
PEN
+$47.5M
5
XNCR icon
Xencor
XNCR
+$46.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.51%
2 Miscellaneous 2.32%
3 Financials 2.17%
4 Energy 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMRX
51
DELISTED
Chimerix, Inc.
CMRX
$15.4M 0.44%
3,558,388
+21,670
+0.6% +$66.7K
HOOK
52
DELISTED
HOOKIPA Pharma
HOOK
$12.7M 0.36%
+189,188
New +$20.1M
PSNL icon
53
Personalis
PSNL
$1.82B
$10.9M 0.31%
+400,000
New +$11.3M
LOGC
54
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$10.6M 0.3%
814,898
-94,889
-10% -$1.26M
GBT
55
DELISTED
Global Blood Therapeutics, Inc.
GBT
$9.89M 0.28%
188,000
+20,400
+12% +$1.17M
GTHX
56
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$8.97M 0.25%
+292,734
New +$6.16M
NVTA
57
DELISTED
Invitae Corporation
NVTA
$8.82M 0.25%
375,375
-998,800
-73% -$21.3M
BMRN icon
58
CALL
BioMarin Pharmaceuticals
BMRN
$12.5B
$8.56M 0.24%
+100,000
New +$8.55M
BMRN icon
59
BioMarin Pharmaceuticals
BMRN
$12.5B
$8.32M 0.24%
+97,191
New +$8.31M
PRNB
60
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$8.1M 0.23%
+244,100
New +$7.62M
GOSS icon
61
Gossamer Bio
GOSS
$83.2M
$5.51M 0.16%
248,600
-1,400
-0.6% -$26.8K
ONC
62
BeOne Medicines Ltd
ONC
$41.5B
$4.95M 0.14%
39,900
-500
-1% -$63.5K
AVDR
63
DELISTED
Avedro, Inc Common Stock
AVDR
$4.25M 0.12%
216,200
+91,200
+73% +$1.46M
FTSV
64
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$2.48M 0.07%
+234,000
New +$3.43M
OVID icon
65
Ovid Therapeutics
OVID
$547M
$1.36M 0.04%
737,550
– –
JNCE
66
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.26M 0.04%
254,590
– –
ELGX
67
DELISTED
Endologix Inc
ELGX
$570K 0.02%
78,755
-1
-0% -$7
VCEL icon
68
Vericel Corp
VCEL
$2.1B
$316K 0.01%
16,720
– –
MYOK
69
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$313K 0.01%
6,252
– –
AMED
70
DELISTED
Amedisys
AMED
$282K 0.01%
+2,320
New +$275K
HZNP
71
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$274K 0.01%
+11,400
New +$289K
FLXN
72
DELISTED
Flexion Therapeutics, Inc.
FLXN
$266K 0.01%
21,630
– –
ADVM
73
DELISTED
Adverum Biotechnologies
ADVM
$264K 0.01%
2,224
– –
LHCG
74
DELISTED
LHC Group LLC
LHCG
$259K 0.01%
2,166
– –
NBIX icon
75
Neurocrine Biosciences
NBIX
$15.7B
$231K 0.01%
+2,740
New +$225K
1 2
3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2019 Portfolio in Review

As of Q2 2019, Redmile Group held 99 positions worth $3.53B, up 3.4% from $3.42B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group's Q2 2019 filing shows 17 new, 28 increased, 21 reduced and 18 closed positions. Its largest new stake was Sarepta Therapeutics: 412,000 shares worth $62.6M. The largest sale was InflaRx, an estimated $82.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Miscellaneous and Financials.

  • Redmile Group's largest Q2 2019 buy was Sarepta Therapeutics: 412,000 shares worth $62.6M.
  • Redmile Group added most to Tricida, Inc. Common Stock in Q2 2019, an estimated $51.2M increase.
  • Redmile Group's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $62.3M.
  • Redmile Group fully exited InflaRx in Q2 2019, selling an estimated $82.5M.
  • Redmile Group's ten largest holdings make up 48% of its $3.53B portfolio in Q2 2019.
  • Redmile Group opened 17 new positions and closed 18 in Q2 2019.
  • Redmile Group's portfolio value rose 3.4% quarter-over-quarter to $3.53B.

Based on Redmile Group's 13F filing for Q2 2019, filed 14 Aug 2019.